News | Nuclear Imaging | December 26, 2019

Dr. Thomas Chaly pushes for approval of imaging agent to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., poses in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

Feinstein Institutes' Thomas Chaly, Ph.D., in front of a PET-CT imaging machine. He has been instrumental in pushing for FDA approval of a new PET imaging agent, Fluorodopa F-18 (FDOPA), to combat Parkinson’s

December 26, 2019 — The Feinstein Institutes for Medical Research has received U.S. Food and Drug Administration (FDA) approval for a new positron emission tomography (PET) drug to combat Parkinson’s disease. Fluorodopa F-18 (FDOPA) Injection (NDA 200655) will help visualize dopaminergic nerve terminals in the striatum for the evaluation of patients with suspected Parkinsonian syndromes.

Thomas Chaly, Ph.D., chief of cyclotron/radiochemistry at the Feinstein Institutes, was instrumental in getting this FDA approval. “This FDA approval is the pinnacle of our venture to have a safe and effective imaging agent for the differential diagnosis of Parkinsonian Syndromes,” said Chaly, who is also an associate investigator in the Institute of Molecular Medicine.

A PET scan is an imaging test that helps to understand the disease condition of the organs at the cellular level. PET uses a short-lived radiopharmaceutical to visually observe the affected area of the organ. In patients with Parkinson’s disease who experience loss of dopaminergic neurons, FDOPA uptake will be lower and this reduced uptake can be visually observed in the PET scan.

Fluorodopa F-18 Injection Helps Visualize Dopaminergic Nerve Terminals

Fluorodopa PET can be used to follow the disease’s progression. In addition, in patients with Parkinson’s disease who have received intracerebral transplantation of adrenal medulla tissue or fetal mesencephalic tissue, FDOPA PET may help to study the integrity and activity of the implant.

“With this approval, PET centers across the United States can incorporate FDOPA F-18 into their diagnostic and treatment follow up programs for patients with Parkinson’s disease,” Chaly said.   

David Eidelberg, M.D., and Vijay Dhawan, Ph.D., helped direct the clinical studies for this NDA approval.

Fluorodopa F-18 Injection is injected into a vein in preparation for a PET scan to help detect the damaged or lost dopaminergic nerve cells. It is to be used in addition to other tests for diagnosing Parkinsonian syndromes. 

To learn more about Fluorodopa F-18 trial. 


Related Content:

PET Aids Dopamine Cell Transplantation for Parkinson’s Patients

Trends in Molecular Imaging

Radiopharmaceutical Product Receives Positive Opinion in Europe

Related Content

News | Lung Imaging

January 23, 2023 — A study published in the January issue of The Journal of Nuclear Medicine reports that approximately ...

Time January 23, 2023
News | Cardiac Imaging

January 13, 2023 — Nuclear stress testing performed with single-photon emission computed tomography (SPECT) is the most ...

Time January 13, 2023
News | Radiopharmaceuticals and Tracers

January 11, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time January 11, 2023
News | Molecular Imaging

January 5, 2023 — A new study has determined that approximately three percent of all bone scan patients have markers of ...

Time January 04, 2023
News | Proton Therapy

January 2, 2023 — IBA, a world leader in particle accelerator technology, today confirms that it has signed a contract ...

Time January 02, 2023
News | Nuclear Imaging

January 2, 2023 — The federal agency that oversees the administration of nuclear medicine has announced that it will ...

Time January 02, 2023
News | Clinical Trials

December 14, 2022 — CytoSite Bio, a company developing precision imaging products that determine patient response to ...

Time December 14, 2022
News | Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time December 02, 2022
News | Proton Therapy

November 25, 2022 — Researchers at the University of Wisconsin–Madison, the first U.S. clinical evaluation site for GE ...

Time November 25, 2022
News | Magnetic Resonance Imaging (MRI)

November 21, 2022 — You can keep your best guesses. Engineers at Rice University’s George R. Brown School of Engineering ...

Time November 21, 2022
Subscribe Now